ChromaDex Management

Management criteria checks 2/4

ChromaDex's CEO is Rob Fried, appointed in Jun 2018, has a tenure of 5.83 years. total yearly compensation is $1.16M, comprised of 43.1% salary and 56.9% bonuses, including company stock and options. directly owns 2.09% of the company’s shares, worth €5.08M. The average tenure of the management team and the board of directors is 4.2 years and 7 years respectively.

Key information

Rob Fried

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage	43.1%
CEO tenure	5.8yrs
CEO ownership	2.1%
Management average tenure	4.2yrs
Board average tenure	7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Rob Fried's remuneration changed compared to ChromaDex's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$1m	US$500k	-US$5m
Sep 30 2023	n/a	n/a	-US$6m
Jun 30 2023	n/a	n/a	-US$6m
Mar 31 2023	n/a	n/a	-US$11m
Dec 31 2022	US$1m	US$500k	-US$17m
Sep 30 2022	n/a	n/a	-US$20m
Jun 30 2022	n/a	n/a	-US$28m
Mar 31 2022	n/a	n/a	-US$27m
Dec 31 2021	US$1m	US$500k	-US$27m
Sep 30 2021	n/a	n/a	-US$28m
Jun 30 2021	n/a	n/a	-US$23m
Mar 31 2021	n/a	n/a	-US$21m
Dec 31 2020	US$1m	US$519k	-US$20m
Sep 30 2020	n/a	n/a	-US$23m
Jun 30 2020	n/a	n/a	-US$26m
Mar 31 2020	n/a	n/a	-US$30m
Dec 31 2019	US$2m	US$487k	-US$32m
Sep 30 2019	n/a	n/a	-US$32m
Jun 30 2019	n/a	n/a	-US$33m
Mar 31 2019	n/a	n/a	-US$33m
Dec 31 2018	US$5m	US$379k	-US$33m
Sep 30 2018	n/a	n/a	-US$34m
Jun 30 2018	n/a	n/a	-US$29m
Mar 31 2018	n/a	n/a	-US$23m
Dec 30 2017	US$4m	US$231k	-US$17m

Compensation vs Market: Rob's total compensation ($USD1.16M) is above average for companies of similar size in the German market ($USD691.02K).

Compensation vs Earnings: Rob's compensation has increased whilst the company is unprofitable.

CEO

Rob Fried (63 yo)

5.8yrs

Tenure

US$1,160,206

Compensation

Mr. Robert N. Fried, also known as Rob, has been the Chief Executive Officer of ChromaDex Corp. since June 22, 2018 and its a Director since July 2015. Mr. Fried was the Chief Operating Officer of ChromaDe...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Frank Jaksch	Co-Founder & Chairman	24.2yrs	US$92.31k	3.06% $ 7.4m
Robert Fried	CEO & Director	5.8yrs	US$1.16m	2.09% $ 5.1m
Brianna Gerber	Chief Financial Officer	1.7yrs	US$691.59k	0.038% $ 92.2k
Andrew Shao	Senior Vice President of Global Regulatory & Scientific Affairs	4.2yrs	no data	no data
Heather Van Blarcom	Senior VP of Legal & Corporate Secretary	2.3yrs	no data	no data
Alex Worsham	Vice President of Global Marketing & Communications	no data	no data	no data
David Kroes	Senior Vice President of People Matters	no data	no data	no data
Chu Yan	Managing Director of Asia Pacific	5.5yrs	no data	no data
Jason Campbell	Senior Vice President of Business Development	less than a year	no data	no data
Kendall Knysch	Head of Media Relations & Partnerships	no data	no data	no data

4.2yrs

Average Tenure

55yo

Average Age

Experienced Management: OCD1's management team is considered experienced (4.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Frank Jaksch	Co-Founder & Chairman	24.2yrs	US$92.31k	3.06% $ 7.4m
Robert Fried	CEO & Director	8.8yrs	US$1.16m	2.09% $ 5.1m
Rudolph Tanzi	Member of Scientific Advisory Board	6.8yrs	no data	no data
Steven Rubin	Lead Independent Director	7.1yrs	US$117.31k	0.0093% $ 22.5k
Roger Kornberg	Chairman of the Scientific Advisory Board	9.8yrs	no data	no data
J. German	Member of Scientific Advisory Board	9.6yrs	no data	no data
Ann Cohen	Independent Director	2yrs	US$89.81k	0% $ 0
Wing Yu	Non-Executive Director	6.7yrs	US$67.31k	0% $ 0
Kristin Patrick	Independent Director	2yrs	US$82.31k	0% $ 0
Charles Brenner	Chief Scientific Advisor & Member of Scientific Advisory Board	9.6yrs	no data	no data
John Walker	Member of Scientific Advisory Board	5.9yrs	no data	no data
Brunie Felding	Member of the Scientific Advisory Board	4.8yrs	no data	no data

7.0yrs

Average Tenure

62.5yo

Average Age

Experienced Board: OCD1's board of directors are considered experienced (7 years average tenure).

ChromaDex Management

Management criteria checks 2/4

Key information

Recent management updates

ChromaDex Corporation, Annual General Meeting, Jun 20, 2024

ChromaDex Appoints Dr. Vilhelm Bohr to Its Scientific Advisory Board

Chromadex Corporation Names Brianna Gerber Chief Financial Officer

Insider recently bought €1.2m worth of stock

Chromadex Corporation Announces Executive Changes

Less than half of directors are independent

Recent updates

ChromaDex Corporation, Annual General Meeting, Jun 20, 2024

ChromaDex Corporation to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: US$0.066 loss per share (vs US$0.24 loss in FY 2022)

ChromaDex Corporation to Report Q4, 2023 Results on Mar 06, 2024

Neurohacker Collective and Chromadex Partner to Optimize Cellular Health with the Debut of Qualia Nad+

Ch ChromaDex Corp. shares results from a new breakthrough study analyzing the safety of high-dose nicotinamide riboside (NR) supplementation on individuals with Parkinson's disease (PD)

Chromadex Corp. Shares Results from Phase II Clinical Study

Third quarter 2023 earnings released: US$0.013 loss per share (vs US$0.014 loss in 3Q 2022)

ChromaDex Corporation Provides Revenue Guidance for the Year 2023

ChromaDex Corp. Debuts Clinical Strength Tru Niagen®? Pro 1,000Mg Featuring Niagen®? (Patented Nicotinamide Riboside)

ChromaDex Corporation to Report Q3, 2023 Results on Nov 08, 2023

ChromaDex Corp. and Zesty Paws Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line

New minor risk - Market cap size

Chromadex Announces Results from Newly Published Clinical Study, as Reported in the Peer-Reviewed Journal Cell Reports, Demonstrating That Supplementation with Nicotinamide Riboside

Second quarter 2023 earnings released: US$0.029 loss per share (vs US$0.094 loss in 2Q 2022)

Forecast to breakeven in 2025

ChromaDex Corporation to Report Q2, 2023 Results on Aug 09, 2023

ChromaDex Corp. Announces Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD) in Glaucoma Patients and That Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects

First quarter 2023 earnings released: US$0.025 loss per share (vs US$0.11 loss in 1Q 2022)

Forecast to breakeven in 2025

ChromaDex Corporation Provides Revenue Guidance for the Full Year 2023

Full year 2022 earnings released: US$0.24 loss per share (vs US$0.40 loss in FY 2021)

ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients

ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis

ChromaDex Appoints Dr. Vilhelm Bohr to Its Scientific Advisory Board

Chromadex Corporation Names Brianna Gerber Chief Financial Officer

Forecast to breakeven in 2025

ChromaDex Corporation Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside Increase Nicotinamide Adenine Dinucleotide Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers

Chromadex Corp. Reports FDA’S Conclusion That Nicotinamide Mononucleotide (Nmn) May Not Be Sold or Marketed as A Dietary Supplement in the United States

Third quarter 2022 earnings released: US$0.014 loss per share (vs US$0.13 loss in 3Q 2021)

ChromaDex Corporation Provides Earnings Guidance for the Year 2022

ChromaDex Corporation to Report Q3, 2022 Results on Nov 02, 2022

Chromadex Shares Promising Findings from Clinical Study Showcasing The Safety and Tolerability of Nicotinamide Riboside (Nr) in Heart Failure with Reduced Ejection Fraction

Insider recently bought €1.2m worth of stock

Second quarter 2022 earnings released: US$0.094 loss per share (vs US$0.082 loss in 2Q 2021)

Chromadex Corporation Announces Executive Changes

ChromaDex Corporation to Report Q2, 2022 Results on Aug 10, 2022

ChromaDex Corporation(NasdaqCM:CDXC) dropped from Russell 2000 Dynamic Index

Less than half of directors are independent

ChromaDex Corporation Announces Directors Changes

Insider recently bought €95k worth of stock

ChromaDex Corporation Announces Resignation of Frank L. Jaksch, Jr as Executive Director, with Effect from June 30, 2022

No longer forecast to breakeven

First quarter 2022 earnings released: US$0.11 loss per share (vs US$0.12 loss in 1Q 2021)

ChromaDex Corporation Appoints Kristin Patrick and Ann Cohen to Its Board of Directors

ChromaDex Corporation to Report Q1, 2022 Results on May 12, 2022

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

ChromaDex Corporation Announces Board Changes

Caroline Levy Notifies Her Intention to Resign from the Board and as Member of the Audit Committee and Nominating and Corporate Governance Committee of the Board of Chromadex Corporation

Kurt Gustafson Announces Not to Stand for Re-Election as director of Board of Directors of the Company and as a member of the Audit Committee and Compensation Committee of the Board of ChromaDex Corporation

Jeffery Baxter Notifies His Intention to Resign from Board of ChromaDex

ChromaDex Corp. Launches Tru Niagen Immune, Further Expanding Innovative Product Portfolio

CEO & Director recently bought €49k worth of stock

CEO & Director recently bought €49k worth of stock

CEO & Director recently bought €49k worth of stock

Forecast breakeven date pushed back to 2024

ChromaDex Corporation to Report Q4, 2021 Results on Mar 09, 2022

ChromaDex Corp. Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.068 loss in 3Q 2020)

Forecast to breakeven in 2023

Insider recently bought €1.8m worth of stock

ChromaDex Corporation Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program

Second quarter 2021 earnings released: US$0.082 loss per share (vs US$0.061 loss in 2Q 2020)

Chromadex Corporation Provides Earnings Outlook for the Full Year 2021

ChromaDex Corp. Shares Research Findings from the ChromaDex External Research Program

ChromaDex Corp. and Walmart Launch Tru Niagen in 3,800 Walmart Stores Across the United States

CEO & Director recently bought €55k worth of stock

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.099 loss in 1Q 2020)